Fahrenholtz, C. D., Beltran, P. J., & Burnstein, K. L. (2013). Targeting IGF-1R with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts.
Citação norma ChicagoFahrenholtz, Cale D., Pedro J. Beltran, and Kerry L. Burnstein. Targeting IGF-1R With Ganitumab Inhibits Tumorigenesis and Increases Durability of Response to Androgen-deprivation Therapy in VCaP Prostate Cancer Xenografts. 2013.
Citação norma MLAFahrenholtz, Cale D., Pedro J. Beltran, and Kerry L. Burnstein. Targeting IGF-1R With Ganitumab Inhibits Tumorigenesis and Increases Durability of Response to Androgen-deprivation Therapy in VCaP Prostate Cancer Xenografts. 2013.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.